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Abstract
Since the discovery of cisplatin more than 40 years ago and its clinical introduction in the 1970s an enormous amount of
research has gone into elucidating the mechanism of action of cisplatin on tumor cells. With a novel cell biosensor chip system
allowingcontinuousmonitoringofrespiration,glycolysis,andimpedancewefollowedcisplatintreatmentofdifferentcancercell
linesinreal-time.Ourmeasurementsrevealafirsteffectonrespiration,inallcisplatintreatedcelllines,followedwithasignificant
delay by interference with glycolysis in HT-29, HCT-116, HepG2, and MCF-7 cells but not in the cisplatin-resistant cell line MDA-
MB-231. Most strikingly, cell death started in all cisplatin-sensitive cell lines within 8 to 11 h of treatment, indicating a clear time
frame from exposure, first response to cisplatin lesions, to cell fate decision. The time points of most significant changes were
selected for more detailed analysis of cisplatin response in the breast cancer cell line MCF-7. Phosphorylation of selected signal
transduction mediators connected with cellular proliferation, as well as changes in gene expression, were analyzed in
samples obtained directly from sensor chips at the time points when changes in glycolysis and impedance occurred.
Our online cell biosensor measurements reveal for the first time the time scale of metabolic response until onset of cell death
under cisplatin treatment, which is in good agreement with models of p53-mediated cell fate decision.
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Introduction
Cisplatin has been used in cancer chemotherapy for more than
30 years against different human tumors, since its approval by the
FDA in 1978 [1], [2]. DNA is the proven primary target of
cisplatin, and cisplatin adduct formation effects many DNA-
dependent cellular functions, including inhibition of replication
and transcription, cell cycle arrest, and DNA damage leading to
cell death and apoptosis, but may also result in mutations [3], [4],
[5], [6]. Despite clarity about the basic mechanism of cisplatin
toxicity leading to induce cell death in sensitive cells [3], it still
remains unclear how cisplatin triggers cell death over time in a cell
population. We used a cell biosensor chip system for continuous
monitoring of changes in cell metabolism and cell morphology for
time-resolved analysis of cisplatin action on tumor cells including
the breast cancer cell lines MCF-7 (p53 wild type) and MDA-MB-
231 (p53 mutant), the colon cancer cell lines HT-29 and HCT-
116, and the hepatocellular carcinoma HepG2.
The biosensor chip system used (Bionas 2500) allows simulta-
neous measurement o f several metabolic parameters of the
specific cells grown on the biosensor chip (Fig. 1A–B), in our case
(i) glycolytic activity measured as pH change, (ii) cellular
respiration measured as oxygen consumption, and (iii) cellular
morphology, adhesion, cell–cell interactions, and membrane
functionality measured as cellular impedance [7], [8], [9].
Monitoring the cellular response to cisplatin in real time we
observed distinct time profiles for changes in respiration, glycolysis,
and impedance. The observed drastic change of impedance is a
clear indicator for the onset of cell death. Although respiration was
the first parameter affected by cisplatin, experiments with isolated
mitochondria showed no immediate effect of cisplatin on
mitochondrial respiratory activity in a time frame when respiration
of intact cells was clearly reduced. At time points of most
significant changes in the breast cancer cell line MCF-7 we
performed more detailed analysis of signal transduction connected
with cell proliferation and of gene expression. Interestingly, no
significant change of analyzed pathways could be detected when
glycolysis and impedance changes occurred, at 8 and 11 h upon
cisplatin treatment, respectively, while after 24 h a decrease in p-
Akt1 and p-GSK-3b reflected reduced pro-survival signaling. Pro-
apoptotic regulation was visible by changes in gene expression.
Expression of several pro-apoptotic genes was already induced
when glycolysis changed and much more so when impedance
changed at onset of cell death. In contrast, stress response genes
were strongly regulated when glycolysis changed but did not show
much further induction when impedance changed. This suggests
that in response to cisplatin, first an initial general stress response is
activated before pro-apoptotic cell fate decision. The time frames
observed in our online measurements indicate that this crucial
transition occurs at around 10 h upon cisplatin treatment.
Results
Changes in cellular metabolism in response to cisplatin
Cisplatin was applied to the cancer cell lines MCF-7, HT-29,
HCT-116, and HepG2 and the response measured by the cell
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respond immediately to cisplatin. It rather took about 5–6 h
before cellular respiration decreased, followed by an increase in
glycolysis after 8–9 h upon treatment with 50 mM cisplatin. After
these metabolic changes a drastic decrease in cellular impedance
occurred at about 10–11 h after exposure to cisplatin (Fig. 2 C),
which reflects the onset of cisplatin induced cell death. High
cisplatin concentrations showed a more rapid and severe response.
This response profile is very characteristic for MCF-7 cells. The
colon carcinoma cells, HT-29 and HCT-116, show a significantly
different response. Both cell lines show an immediate decrease in
respiration but no significant change in glycolysis before cells
started to die, seen by a significant decrease of impedance at about
8–9 h in HCT-116 cells and at about 10–11 h in HT-29 cells
(Fig. 2F, I). Cell death is also reflected in the complete reduction of
metabolism, in particular the decrease of glycolysis slightly pre-
running the impedance change. The transient increase of
impedance visible in HCT-116 cells (Fig. 2I) was observed in all
experiments and indicates a change in cell interactions in response
to the treatment before induction of cell death.
Treatment of HepG2 cells also led to an immediate decrease in
respiration and a delayed decrease in glycolysis (Fig. 1J–L). Again
cells start to die independent of the applied cisplatin concentration
after about 8–9 h, although the extent of cell death is
concentration dependent. An overview of the response time frame
of the above cell lines to 50 mM cisplatin is presented in Table 1.
Regarding the cisplatin-resistant breast cancer cell line MDA-MB-
231 it should be noted that, while cisplatin had no effect on
glycolysis and cellular impedance, a decrease in respiration could
be observed at the highest (50 mM) cisplatin concentration, clearly
indicating that these cells sense cisplatin but are not sensitive to
cisplatin induced cell death (Fig. 3).
It should be emphasized, however, that none of the sensitive
cells lines showed a recovery, even with lower cisplatin
concentrations, when cisplatin was removed from the medium
after 24 h of treatment (Fig. 2A–L).
Measurement of mitochondrial oxygen consumption
Because of the immediate effect of cisplatin on respiration of
colon cancer and liver cancer cell lines, we decided to analyze
whether cisplatin directly affects mitochondrial respiration using a
mitochondrial activity assay with isolated mouse liver mitochon-
dria (Fig. 4). While the well-established mitochondrial inhibitor
rotenone and the uncoupler CCCP clearly blocked and increased
mitochondrial activity, respectively, cisplatin had no effect on
mitochondrial respiration within 4–5 h, independent of the
cisplatin concentration used. This clearly shows that respiratory
changes observed with intact cells in the cell biosensor system must
have resulted from a cellular response to cisplatin treatment.
We therefore analyzed the formation of ROS in response to
cisplatin treatment after 6, 10, 12, 24 h in MCF-7 and HT-29
cells, assuming that ROS could be a mediator of early cisplatin
response, including respiration change, and also an important
mediator of cisplatin-induced cell death [10]. Surprisingly, no
significant ROS formation could be detected in MCF-7 and HT-
29 cells treated with 50 mM cisplatin (Fig. 5).
Glycolysis decreases after 6–7 h in the colorectal cancer cell line
HCT-116 and in HepG2 or after 9–10 h in the colorectal cancer
cell line HT-29. This is slightly before or at about the same time
when impedance decreased. In striking contrast, glycolysis was
stimulated in the breast cancer cell line MCF-7 around 8 h after
start of treatment, clearly before cells started to die in the biosensor
assay. This pronounced difference between MCF-7 and all other
cell lines led us to analyze the basic metabolic activity. Raw values
of basic respiratory and glycolytic activity show that MCF-7 cells
had the lowest glycolytic but the highest respiration rate. In
contrast, HT-29 had the lowest respiration and a higher glycolytic
activity compared to MCF-7 (Fig. 6).
Cell signaling and gene expression suggest a transition
from general stress response to pro-apoptotic signaling
To obtain a more detailed picture of the cellular response of
MCF-7 cells to cisplatin, we analyzed the phosphorylation of key
signal transduction mediators (Fig. 7A–C) and gene expression
profiles directly from the samples analyzed in the biosensor chip
immediately after the first change in (i) glycolytic rate and (ii)
impedance became visible when treated with 50 mM cisplatin. Our
results do not show any significant change in activation of Akt1,
GSK-3b, and ERK1/2 MAP-kinases within the first 8–11 h
(glycolysis and impedance change) of cisplatin treatment. After
24 h a significant decrease in p-Akt1 and p-GSK-3b reflects
reduced pro-survival signaling, which was even more pronounced
after a shorter pulse with 50 mM cisplatin than with continuous
lower (10 mM) treatment (Fig. 7). The specific efficiency of 50 mM
cisplatin treatment is also supported by an increased level of p-
ERK1, which was shown to contribute to apoptosis induction by
cisplatin [11].
This specific pro-apoptotic regulation is also confirmed by
changes in gene expression recorded at the time of glycolysis and
impedance change (GEO NCBI Accession number: GSE28274).
Using a 1.75-fold change and a minimal normalized signal of 100
as cutoff we obtained 1338 significantly regulated probe sets, of
Figure 1. Outline of the cell biosensor chip system. A, schematic diagram of the flow system for biosensor chip analysis, showing the inlet and
outlet for running medium and the small incubation chamber. B, picture of cells (HT29) growing on biosensor chip. Electrode sensors are visible and
marked: ISFET: pH sensor; Clark-type sensor: O2 sensor; IDESs; interdigitated electrodes for impedance measurements.
doi:10.1371/journal.pone.0019714.g001
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Table S1). Most genes were differentially expressed at both time
points, but a significant number was stronger regulated at the later
time point of impedance change. Top-regulated genes for each
treatment are shown in supplemental Table S2. While strongly
regulated genes at glycolysis change, were not further induced, the
top list from impedance change shows several genes significantly
more changed within the additional (about) 2 h between the two
time points analyzed before cells started to die (impedance
change). The reliability of the gene expression profiles was
confirmed by quantitative real-time RT-PCR analysis of selected
genes in independent experiments (Fig. 8A–B).
Further analysis by gene ontology and pathway annotation
using DAVID [12], [13] showed an enrichment of genes
Figure 2. Real-time response profiles of cellular respiration, glycolysis, and impedance upon cisplatin treatment. Cisplatin treatment
started after 5 h of equilibration of cancer cell tissue cultures in the biosensor chip system and was continued over 24 h. RM (running medium) marks
cisplatin-free medium; exposure marks time when cisplatin was presented at indicated concentrations (cisplatin-free control, 5 mM, 10 mM, 25 mM,
50 mM). A,D,G,J, change in respiration (oxygen in the medium), B,E,H,K, glycolysis, depicted as change in acidification of the medium (extracellular pH),
C,F,I,L, change in impedance of the cell layer (potential between interdigitated electrodes) using four cancer cells lines, A,B,C, MCF-7, D,E,F, HT-29,
G,H,I, HCT-116, and J,K,L, HepG2. Arrows indicate the time points of significant changes at the highest concentration (50 mM) of cisplatin used.
doi:10.1371/journal.pone.0019714.g002
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change of impedance were clearly enriched for p53-signaling
(p=0.0023), cell cycle control (cyclin-dependent protein kinase
activity: p=0.001), and programmed cell death (apoptosis:
p=0.0058). Down-regulated genes were enriched for various cell
proliferation-associated cell processes, in particular, wnt (p=
0.000008), tgfb (p=0.0019), MAP-kinase (p=0.0016), hedgehog
(p=0.0033), and erbb (p=0.000082) signaling (supplemental
Table S3).
The pro-apoptotic regulation is well reflected in the main
regulatory circuit of p53 control, with up-regulation of E2F1, but
down-regulation of E2F3 (Fig. 8C). Analysis of genes already
significantly induced at glycolysis, suggests that at first a general
stress response including cell cycle arrest is activated, before
induction of cell death occurs; gene groups significantly up-
regulated at glycolysis change include: response to protein
stimulus, regulation of cyclin-dependent protein kinase activity,
stress response, response to organic substance (p,0.05). The
complex regulatory activities, from initial stress response and
transition to apoptosis, are also reflected in the strong induction
of p53 signaling mediators (Fig. 8), namely ATF3 a mediator of
p53 signaling, the pro-apoptotic proteins TSP1, maspin,
NOXA(PMAIP1), and the cell cycle regulator GADD45A, as
well as the down-regulation of CDK6, required for cell cycle
progression.
Discussion
In this study we used a novel cell biosensor chip to follow, in real
time, the metabolic response to cisplatin, one of the best-studied
anticancer agents. Cisplatin treatment leads to immediate as well
as delayed metabolic adaptations (measured as respiration and
acidification) and changes in cell–cell interaction and adhesion
(measured as impedance). The first cellular response observed after
initiation of treatment provides a specific time-resolved insight in
cisplatin toxicity and hints to the possible molecular mechanism.
We performed real-time measurements of five cancer cell lines:
two types of breast cancer cell lines (MCF-7 and MDA-MB-231),
two types of colorectal cancer cell lines (HT-29 and HCT-116),
and the liver hepatocellular carcinoma HepG2. In all cells, oxygen
consumption was the first parameter to be affected by cisplatin,
either almost immediately after cisplatin treatment started, as in
HT-29, HCT-116, HepG2, and MDA-MB-231, or after 5–6 h in
the case of MCF-7 cells. This appears to confirm the hypothesis
that mitochondria are a primary target of cisplatin-mediated DNA
damage [14], [15], indicating that cisplatin accumulates in
Figure 3. Real-time response profiles of cellular respiration, glycolysis, and impedance upon cisplatin treatment of cisplatin-
resistant breast cancer cell line MDA-MB-231. Cisplatin treatment started after 5 h of equilibration of cancer cell tissue cultures in the biosensor
chip system and was continued over 20 h. RM (running medium) marks cisplatin free medium; exposure marks the time when cisplatin was
presented at the indicated concentrations (cisplatin-free control, 10 mM, 25 mM, 50 mM). A, change in respiration (oxygen in the medium). B,
glycolysis, depicted as change in acidification of the medium (extracellular pH). C, change in impedance of the cell layer (potential between
interdigitated electrodes) using four cisplatin-resistant breast cancer cell lines MDA-MB-231.
doi:10.1371/journal.pone.0019714.g003
Table 1. Time points of metabolic and impedance changes in response to 50 mM cisplatin.
Cancer cell line Respiration change/hour Glycolysis change/hour Impedance change/hour
MCF-7 5–6 (Decrease) *8–9 (Increase)
10–11 (Decrease)
10–11 (Decrease)
HT-29 Immediate response (Decrease) 9–10 (Decrease) 10–11 (Decrease)
HCT-116 Immediate response (Decrease) 6–7 (Decrease) *4–5 (Increase)
8–9 (Decrease)
HepG2 Immediate response (Decrease) 6–7 (Decrease) 8–9 (Decrease)
*Denotes two transitions for one parameter: here, an increase precedes the final decrease of the measured value.
doi:10.1371/journal.pone.0019714.t001
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mitochondrial damage.
Our results with isolated mitochondria showed no immediate
effect on mitochondrial activity in a time frame when respiration
of intact cells is clearly reduced. This correlates with previous
observations that lower concentrations of cisplatin do not inhibit
activity of isolated rat liver mitochondria [14]. Thus, the
immediate respiratory response to cisplatin must result from a
mitochondrial activity-independent mechanism involving cellular
signaling or DNA damage. However, because it is also observed in
the p53 mutant cell line MDA-MB-231, DNA damage-mediated
signaling may not be the primary cause.
Glycolysis, on the other hand, decreases after 6–7 h in the
colorectal cancer cell line HCT-116 and in HepG2 cells which
occurs at about the same time or slightly before impedance
decreased. In striking contrast, glycolysis was stimulated in the
breast cancer cell line MCF-7 around 8 h after start of treatment,
clearly before cells started to die in the biosensor assay. No change
in glycolysis was observed in the cisplatin-resistant cell line MDA-
MB-231. The pronounced difference between MCF-7 and all
other cell lines led us to analyze the basic metabolic activity.
Raw values of basic respiratory and glycolytic activity show that
MCF-7 has the lowest acidification and highest respiration rate. In
contrast, HT-29 had the lowest respiration but higher glycolytic
activity compared to MCF-7. Other stress-inducing compounds
like methyl methanesulfonate (MMS) and tert-butyl hydroperoxide
Figure 4. Respiration of isolated mouse liver mitochondria.
Mitochondrial respiration consumes oxygen, depicted as a decrease of
oxygen saturation over time. After about 50 min mitochondrial
respiration buffer is exhausted, leading to continues reduction of
mitochondrial respiratory activity. activity leads to a decrease in oxygen
saturation, which decreases over time (control). Inhibition of mitochon-
drial activity blocks oxygen consumption, resulting in continuous high
oxygen concentration. Controls: (i) ‘‘Control’’: respiration buffer
without cisplatin; (ii) ‘‘CCCP’’: carbonyl cyanide 3-chlorophenylhydra-
zone uncouples respiration leading to maximum consumption and
complete depletion of oxygen (0%); (iii) ‘‘Rotenone’’: an inhibitor of
respiratory chain complex I, completely abolishes mitochondrial
respiration leaving oxygen concentration unchanged at 100%; (iv)
‘‘Respiration buffer’’: respiration buffer without mitochondria and
without cisplatin. In Cisplatin samples, cisplatin was added at the start
of measurement at indicated concentrations (5 mM, 10 mM, 25 mM,
50 mM). No difference between control (without cisplatin) and cisplatin
treatment is visible.
doi:10.1371/journal.pone.0019714.g004
Figure 5. Intracellular ROS formation. MCF-7 and HT-29 were
treated with 50 mM cisplatin for the indicated incubation times (6 h,
10 h, 12 h, and 24 h). As positive control, cells were treated with
500 mM tBHP (tert-butyl hydroperoxide) for 3 h. No significant induction
of intracellular ROS with 50 mM cisplatin was observed at the analyzed
time points.
doi:10.1371/journal.pone.0019714.g005
Figure 6. Cell-type specific basal levels of metabolism and cell layer impedance. Basal level of oxygen consumption, acidification of
medium, and cell impedance recorded in the cell biosensor chip without drug treatment and at the beginning of experiments before treatment with
cisplatin; A, basal respiratory activity (change of oxygen of medium); B, basal glycolytic rate (change of extracellular pH); C, relative difference of
electrical capacity in comparison to cell-free biosensor chip.
doi:10.1371/journal.pone.0019714.g006
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cell lines tested in this work that were able to enhance glycolysis
when respiration was inhibited, while HT-29 cells were able to
increase respiration in stress conditions (supplemental Fig. S1A–L).
We also showed previously that MCF-7 and HT-29 cells respond
differently to other cytotoxic compounds regarding glycolysis and
respiration [16], [17].
Impedance measurements reflect cell morphological and cell
adhesion changes, e.g., cell-cell and cell-matrix contacts. MCF-7
cells treated with cisplatin showed a rapid decline of impedance
after 10–11 h in a dose-dependent manner. In contrast to MCF-7
cells, HCT-116, HepG2, and HT-29 display a lower rate of
impedance decrease (lower slope) which could indicate lower
sensitivity to cisplatin. This may be explained by a higher basic
levels of glycolysis. In a recent study centered on cisplatin and 2-
deoxy-D-glucose cotreatment, it was suggested that a high basal
glycolytic rate correlates with a more cisplatin-resistant phenotype
[18]; our results seem to confirm this observation. Although the
rate of impedance reduction is different, all cell lines showed
ongoing cell death when cisplatin was removed after 24 h,
indicating persistent cellular damage. This is in good agreement
with DNA damage being the main mode of cisplatin action [3],
[4], [5], [6].
Even after exposure for only 6 h, MCF-7 cells start to die in the
same time frame and do not escape cisplatin-induced cell death
(data not shown).
Cisplatin treatment also had been associated with specific
activation of signaling pathways mediating DNA damage response
and cellular proliferation, including p53, MAP-kinases ERK1/2,
and Akt1 [19], [20], [21]. It has been shown that ERK1
contributes to apoptosis by activating the tumor suppressor p53
[11], [22]. In our experiments no significant change in these key
signaling pathways was observed within the first 8–11 h of
cisplatin treatment. Only after 24 h p-Akt1 and p-GSK-3b levels
were reduced, and p-ERK1 increased at the higher cisplatin
concentration. Thus, these signaling pathways are not primary
mediators of cisplatin-induced cell death but rather mirror
ongoing cell death.
The specific pro-apoptotic regulation is also confirmed by
changes in gene expression, which include a clear induction of pro-
apoptotic genes involved in p53-mediated cell fate decision, such
as TSP1, maspin, PMAIP1(NOXA), and GADD45a. Expression
of these genes was already induced when glycolysis changed and
for some genes increased even further until onset of cell death. In
contrast, stress response genes including HSP70, DUSP1, ID2,
and CYR61 were strongly regulated at glycolysis change without
further induction. This suggests that in response to cisplatin, first
an initial general stress response is activated before pro-apoptotic
cell fate decision occurs. The time frame observed in our online
measurements indicates that this crucial transition occurs around
10 h after onset of cisplatin treatment. Surprisingly, this is in good
agreement with a recently published model of p53-dependent cell
fate decision in response to DNA damage [23]. Our results also
show that p53 target genes are involved in this cell fate decision.
Furthermore, the primary p53 regulatory circuit is clearly
modulated towards p53 activation and pro-apoptotic signaling
by E2F1 and E2F3, the one by an up-regulated and the other by a
down-regulated mechanism.
In essence, for the first time we have been able to show a clear
time line for cisplatin-induced cell death in different cancer cell
lines and to confirm once more that the p53 regulatory circuit is
crucial for this cell fate decision, which is further supported by the
good agreement of our time line measurements with modeling of
the p53 damage response.
Materials and Methods
Real-time monitoring of cellular metabolism in living cells
Changes in cellular metabolism and morphology were analyzed
using a Bionas 2500 sensor chip system (Bionas, Rostock,
Germany). The sensor chips (SC1000) in the Bionas 2500 allow
the continuous measurement of three important parameters of
cellular metabolism: (i) oxygen consumption using Clark-type
electrodes, (ii) change in the pH of the extracellular environment
Figure 7. Change in Akt1 (A), GSK-3b (B), and ERK1 (C) pathway
activity. Concentrations of selected phosphoproteins were measured
with an ELISA microarray in MCF-7 cells at the time points when
glycolysis and impedance were significantly changed with 50 mM
cisplatin treatment, and after 24 h with a 10-h pulse with 50 mM
cisplatin (followed by 14 h with cisplatin-free medium [RM]) or after
continued treatment for 24 h with 10 mM cisplatin. For control, the
concentration of phosphoproteins was measured in untreated cell
samples at the same time points when glycolysis changed in treated
samples (NT start) and at the end of experiments (24 h, NT end).
doi:10.1371/journal.pone.0019714.g007
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between two interdigitated electrode structures to register the
impedance under and across the cell layer on the chip surface.
Before measurement, cells were seeded on the sensor chip in
DMEM with penicillin/streptomycin and 10% (v/v) FCS (PAA)
and incubated in a standard tissue culture incubator at 37uC, 5%
CO2, and 95% humidity for 24 h until 80–90% confluence was
reached. Sensor chips with cells were then transferred to the
Bionas 2500 analyzer in which medium is continuously exchanged
in 8-min cycles (4 min exchange of medium and 4 min without
flow) during which the parameters were measured. The running
medium (RM) used during analysis was DMEM without
carbonate buffer (PAN Cat. Nr. P03-0010) and only weakly
buffered with 1 mM Hepes and reduced FCS (0.1%) and low
glucose (1 g/L). For drug activity testing, the four following steps
were included: (a) 5 h of equilibration with only running medium
Figure 8. Changes in gene expression of key regulators at the time of glycolysis and impedance change in MCF7 cells. To confirm
large-scale gene expression profiling data, selected genes with a focus on p53 signalling were analyzed by quantitative real-time RT-PCR using
independent samples. A–B, real-time RT-PCR shows strong induction of GADD45A, PMAIP1 and ATF3 (A) and low, but significant regulation of MALAT
and SESN1 (up) and CDK6 and E2F3 (down) (B) Control: samples from incubation on biosensor chip without cisplatin treatment; Glycolysis: samples
from biosensor chip at time of glycolysis change (Fig. 1D); Impedance: samples from biosensor chip at time of impedance change (Fig. 1E). Footnote
to Fig. 8. Significance values: * p,0.05; ** p,0.01; *** p,0.001. C, results from gene expression profiling for the same genes.
{E2F1 is included
because it shows similar significance in micro array data as E2F3. Fold change relative to control sample for glycolysis and impedance change.
Impedance/Glycolysis: relative ratio of changes in glycolysis and impedance.
doi:10.1371/journal.pone.0019714.g008
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with compounds freshly dissolved in medium at indicated
concentrations also with 4 min stop/flow, and (c) a drug free step
in which cells are again fed with RM without compound; (d) at the
end of each experiment, cell layers are removed by adding 0.2%
Triton X-100 to obtain basic signals without living cells on the
sensor surface as negative control. Before each experiment, the
tubes of the system were cleaned, washed with 70% EtOH and
then rinsed with PBS and RM.
Cell culture
The cell lines that were used included HT-29, HCT116,
HepG2, MDA-MB-231, and MCF-7 (all from ATCC); all were
cultured in Dulbecco’s modified eagle medium (DMEM) (PAA,
Pasching, Austria), supplemented with 10% FBS (PAA, Pasching,
Austria), 1% penicillin/streptomycin (Gibco Invitrogen) within a
CO2 incubator at 37uC with 5% CO2. For the MDA-MB-231 cell
line we have used Leibovitz’s L-15 Medium (Gibco Invitrogen)
and non-essential amino acids (Gibco invitrogen). All cell lines
were seeded at a density of 2610
5 in each chip in 450 mL DMEM
except MCF-7 with 1.5610
5 per chip. After seeding cells were
grown on the chip for 20–24 h in standard cell culture conditions
to approximately 80–90% confluence on the chip surface at the
time of measurement.
Measurement of mitochondrial oxygen consumption
The measurement was performed using OxoPlateH (PreSens,
Germany), 96-well plates which contain an immobilized oxygen
sensor at the bottom of each well. Fluorescence is measured in
dual mode, excitation 540 nm and emission 650 nm, with
reference emission 590 nm. Their signal ratio 650/590 nm
corresponds to the oxygen partial pressure. The calibration of
the fluorescence reader is performed using a two-point calibration
with oxygen-free water (1% Na2SO3) and air-saturated water with
oxygen partial pressure corresponding to 0% and 100%,
respectively. 18 mg of freshly isolated mitochondria were suspend-
ed in 100 mL of Respiration Buffer (25 mM sucrose, 100 mM
KCl, 75 mM mannitol, 5 mM MgCl2,1 0m MK H 2PO4, 0.5 mM
EDTA, 10 mM Tris, 0.1% fatty acid-free BSA, pH 7.4)
containing 10 mM pyruvate, 2 mM malate, 2 mM ADP, and
0.5 mM ATP to activate oxidative phosphorylation. Cisplatin was
diluted so that the appropriate concentration in the wells was
established after adding the mitochondria. Fluorescence was
measured continuously for 400 min with kinetic intervals of
5 min by a Tecan Safire
2 (Tecan, Maennedorf, Switzerland)
microplate reader at 37uC. During the measurements the plates
were sealed with a breathable membrane (Diversified Biotech,
Boston, MA). Additional controls were 5 mM rotenone (Sigma-
Aldrich) as inhibitor of respiratory chain complex I and 1 mM
CCCP (carbonyl cyanide 3-chlorophenylhydrazone, Sigma-Al-
drich) as uncoupling agent, capable of increasing electron flow
through the respiratory chain thereby increasing the oxygen
consumption.
Antibodies and recombinant protein standards for
protein microarray
Antibody microarrays [24] based on ArrayTube
TM platform
(Clondiag, Jena, Germany) utilize isotype-specific capture anti-
bodies and biotinylated phospho-specific detection antibodies
against 5 human/mouse/rat proteins of interest: phospho-GSK-
3b(S9), phospho-Akt1(S473), phospho-ERK1(T202/Y204), phos-
pho-ERK2(T185/Y187), and phospho-CREB(S133). The micro-
arrays used also antibody pair against human paxillin. Microarray
calibration was performed with recombinant protein standards.
The antibodies and calibration standards were obtained from
R&D Systems, Minneapolis, MN, USA (DuoSetH IC kits). MCF-7
cell protein lysates were isolated directly from the sensor chip at
time points when changes in glycolysis and impedance occur, or at
other time points indicated. Protein quantification was done as
described [25].
RNA isolation, Affymetrix gene-chip hybridization,
reverse transcription and real-time PCR
Total RNA was isolated directly from MCF-7 cells treated in
the Bionas system at time points when changes in glycolysis and
impedance occur using RNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. RNA quality was examined by
agarose gel electrophoresis and concentration was determined by
UV absorbance. Affymetrix array analysis (GeneChipH U133
2.0plus Human Genome) was performed according to the
manufacturer’s protocol. Gene expression profiles were analyzed
using the dChip software [26] and rank based normalization [27];
assignment of functional groups was done using DAVID
Bioinformatics Resources 6.7 (Database for Annotation, Visuali-
zation, and Integrated Discovery) of NIAID (NIH) [12], [13] and
free word data mining. For quantitative RT-PCR 250 ng of total
RNA was reverse transcribed using oligo(dT)18 primer (0.5 mg/
mL, Fermentas) and random hexamers primer (100 mM, Fermen-
tas) and RevertAid
TM Premium Enzyme Mix. Gene expression
was assayed by quantitative real-time PCR on LightCyclerH 480
(Roche Applied Science) using LightCyclerH 480 SYBR Green I
Master with 1 mL cDNA (1:5 dilution of transcribed cDNA) and
the primers listed in Table 2.
Intracellular ROS determination
MCF-7 and HT-29 cell lines (10
5 cells/mL medium) were
treated with 50 mM cisplatin for 6, 10, 12, and 24 h. After
treatment they were trypsinized and resuspended in 1 mL of
Dulbecco’s PBS (Gibco) supplemented with 1% bovine serum
Table 2. List of forward and reverse primers used to perform
quantitative real-time PCR.
Primer name Primer sequence
ATF3-5s 59 – CATCCAGAACAAGCACCTC – 39
ATF3-3as 59 – GCATTCACACTTTCCAGC – 39
CDK6-5s 59 – GATGTGTGCACAGTGTCACGAAC – 39
CDK6-3as 59 – GTGGTTTTAGATCGCGATGCAC – 39
E2F3-5s 59 – GTTCATTCAGCTCCTGAGCCAG – 39
E2F3-3as 59 – CACTTCTTTTGACAGGCCTTGAC – 39
SESN1-5s 59 – CTGAAGAGCATCCAGGAAC – 39
SESN1-3as 59 – GCAGTAGATAGTGCTGAG – 39
MALAT-5s 59 – GGATCCTAGACCAGCATGC – 39
MALAT-3as 59 – GGTTACCATAAGTAAGTTCCAG – 39
GADD45A-5s 59 – CGATAACGTGGTGTTGTGC – 39
GADD45A-3as 59 – GAATGTGGATTCGTCACC – 39
PMAIP1-5s 59 – ATGCCTGGGAAGAAGG– 39
PMAIP1-3as 59 – CAGGTTCCTGAGCAGAAG– 39
Humbetaactin-5s 59 – CTGACTACCTCATGAAGATCCTC– 39
Humbetaactin-3as 59 – CTGCTGAAGAAGCACATCGATTC– 39
doi:10.1371/journal.pone.0019714.t002
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5 cells were then incubated for
15 min in the dark with 10 mM dihydroethidium. Accumulation of
reactive oxygen species (ROS) was measured by flow cytometry
using a FACSCalibur instrument (Becton Dickinson). Excitation
and emission settings were 488 nm and 564–606 nm (FL2 filter),
respectively. Results are presented as a percentage of cells that
showed physiological levels of ROS (low ROS) and a percentage of
cells with a high level of ROS.
Supporting Information
Figure S1 Real-time response profiles of cellular respi-
ration, glycolysis, and impedance upon MMS or tBHP
treatment. MCF-7 breast cancer cells or HT-29 colon
carcinoma cells were treated with the strong stress inducing agents
methyl methanesulfonate (MMS) and tert-butyl hydroperoxide
(tBHP). MMS is a methylating agent which leads to strong
intracellular ROS formation upon methylation of DNA; tBHP is
an organic peroxide that leads to peroxide formation in the
medium. Treatment started after 5 h of equilibration of cancer cell
cultures in the biosensor chip system and continued over 6 h. RM
(running medium) marks time with medium without compound;
exposure period when compounds were present at indicated
concentrations. (A,D,G,J) change in respiration (oxygen in the
medium), (B,E,H,K) glycolysis, depicted as change in acidification
of the medium (extracellular pH), (C,F,I,L) change in impedance
of cell layer (potential between interdigitated electrodes). MCF-7
treated with MMS (A–C); MCF-7 treated with tBHP (G–I); HT-
29 treated with MMS (D–F); HT-29 treated with tBHP (J–L).
(TIF)
Table S1 Genes regulated by cisplatin in MCF-7 cells at change
of (i) glycolysis (8–9 h) and (ii) impedance (10–11 h).
(XLS)
Table S2 Genes regulated by cisplatin in MCF-7 cells at change
of (i) glycolysis (8–9 h) and (ii) impedance (10–11 h).
(XLS)
Table S3 Significantly regulated functional groups*.
(XLS)
Acknowledgments
We would like to thank Nils Metzler-Nolte and colleagues of the DFG-
FOR630 for many helpful discussions. Appreciative thanks are also
extended to Theodor C.H. Cole for his valuable comments and
proofreading of the manuscript.
Author Contributions
Conceived and designed the experiments: SW HA. Performed the
experiments: HA SC PH CS EL IK. Analyzed the data: HA SC PH CS
SW. Contributed reagents/materials/analysis tools: HA SC PH SW.
Wrote the paper: HA SW.
References
1. Rosenberg B, VanCamp L, Krigas T (1965) Inhibition of cell division in
Escherichia coli by electrolysis products from a platinum electrode. Nature 205:
698–699.
2. Wiltshaw E, Kroner T (1976) Phase II study of cis-dichlorodiammineplatinum(II)
(NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:
55–60.
3. Chaney SG, Campbell SL, Bassett E, Wu Y (2005) Recognition and processing
of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53: 3–11.
4. Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM, Marinus MG (2002)
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol
Chem 277: 1255–1260.
5. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs.
Nat Rev Drug Discov 4: 307–320.
6. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:
307–310.
7. Giaever I, Keese CR (1991) Micromotion of mammalian cells measured
electrically. Proc Natl Acad Sci USA 88: 7896–900.
8. Wegener J, Keese CR, Giaever I (2000) Electric cell-substrate impedance sensing
(ECIS) as a noninvasive means to monitor the kinetics of cell spreading to
artificial surfaces. Exp Cell Res 259: 158–66.
9. Ehret R, Baumann W, Brischwein M, Lehmann M, Henning T, et al. (2001)
Multiparametric microsensor chips for screening applications. Fresenius J Anal
Chem 369: 30–35.
10. Huang HL, Fang LW, Lu SP, Chou CK, Luh TY, et al. (2003) DNA-damaging
reagents induce apoptosis through reactive oxygen species-dependent Fas
aggregation. Oncogene 22: 8168–8177.
11. Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, et al. (2005) Role of ERK
activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl
Toxicol 25: 374–382.
12. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
13. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
4: R70.
14. Garrido N, Pe ´rez-Martos A, Faro M, Lou-Bonafonte JM, Ferna ´ndez-Silva P,
et al. (2008) Cisplatin-mediated impairment of mitochondrial DNA metabolism
inversely correlates with glutathione levels. Biochem J 414: 93–102.
15. Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical
target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg
Biomembr 39: 43–50.
16. Rubbiani R, Kitanovic I, Alborzinia H, Can S, Kitanovic A, et al. (2010)
Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors
with multiple antitumor properties. J Med Chem 53: 8608–8618.
17. Harlos M, Ott I, Gust R, Alborzinia H, Wo ¨lfl S, et al. (2008) Synthesis,
biological activity, and structure-activity relationships for potent cytotoxic
rhodium(III) polypyridyl complexes. J Med Chem 51: 3924–3933.
18. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M (2009) Ovarian
carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined
platinum and 2-deoxy-D-glucose treatment. Mol Cancer Ther 8: 1916–1923.
19. Kim HS, Hwang JT, Yun H, Chi SG, Lee SJ, et al. (2008) Inhibition of AMP-
activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via
hyperinduction of p53. J Biol Chem 283: 3731–3742.
20. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three
Akts. Genes Dev 13: 2905–2927.
21. Panka DJ, Cho DC, Atkins MB, Mier JW (2008) GSK-3beta inhibition enhances
sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 283: 726–732.
22. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation
in cisplatin-induced apoptosis. J Biol Chem 275: 39435–39443.
23. Pu T, Zhang XP, Liu F, Wang W (2010) Coordination of the nuclear and
cytoplasmic activities of p53 in response to DNA damage. Biophys J 99:
1696–1705.
24. Wo ¨lfl S, Dummer A, Pusch L, Pfalz M, Wang L, et al. (2005) Analyzing proteins
and proteins modifications with Array Tube
TM antibody microarrays. In:
Schena MI, ed. Protein Microarrays, Jones and Bartlett, London. pp 159–168.
25. Holenya P, Kitanovic I, Heigwer F, Wo ¨lfl S (2011) Microarray-based kinetic
colorimetric detection for quantitative multiplex protein phosphorylation
analysis. Proteomics Accepted manuscript online: 8 MAR 2011 09:21AM EST |
DOI: 10.1002/pmic.201000690.
26. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays:
expression index computation and outlier detection. Proc Natl Acad Sci USA
98: 31–6.
27. Kroll TC, Wo ¨lfl S (2002) Ranking: a closer look on globalisation methods for
normalisation of gene expression arrays. Nucleic Acids Res 30(11): e50.
Time Resolved Cellular Response to Cisplatin
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19714